After years of legal wrangling surrounding Teva’s Copaxone, the latest hit to the lucrative multiple sclerosis drug comes in ...

The drugs’ active ingredient, glatiramer acetate, has been linked to more than 80 cases of anaphylaxis worldwide since ...

Although the revenue and EPS for Teva Pharmaceutical Industries (TEVA) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics ...

Regulatory officials have identified 82 cases worldwide from the FDA Adverse Event Reporting System of anaphylaxis associated ...

The U.S. Food and Drug Administration on Wednesday warned about the risk of a rare but serious allergic reaction with the use ...

Teva Pharmaceutical Industries Limited’s TEVA share price has dipped by 13.89%, which has investors questioning if this is ...

Teva Pharmaceutical’s Copaxone was approved by the FDA in 1996 to treat relapsing forms of MS, an autoimmune disorder that ...

The Food and Drug Administration is adding a boxed warning about the risk of an allergic reaction for Teva‘s (TEVA) Copaxone and Sandoz’s ...

The US Food and Drug Administration (FDA) is warning about the risk of a rare but serious allergic reaction with the medicine ...

The FDA issued a boxed warning for anaphylaxis risk linked to Glatiramer acetate and Glatopa, used in MS treatment.

The FDA is adding a new boxed warning to include information that anaphylaxis can occur at any time, from as early as after ...